2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.Peer-Reviewed Original ResearchConceptsRisk of HCCHigher HIV RNAHCC risk factorsHIV RNAHIV viremiaHepatocellular carcinomaBaseline cirrhosisCirrhosis statusCohort studyRisk factorsCell percentageVeterans Aging Cohort StudyDevelopment of HCCCurrent HIV RNADetectable HIV viremiaHepatitis C coinfectionAging Cohort StudyDiagnosis of cirrhosisLonger durationDetectable HIVLow CD4C coinfectionCurrent CD4Hazard ratioCancer Registry
2006
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort
Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT, Hogg RS, Montaner J. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006, 20: 323-331. PMID: 16439865, DOI: 10.1097/01.aids.0000198091.70325.f4.Peer-Reviewed Original ResearchConceptsInjection drug useAntiretroviral treatmentAntiretroviral therapyLiver injuryHigher plasma albumin levelCombination antiretroviral treatmentHepatitis C serostatusHepatitis C coinfectionPlasma albumin levelsMultivariate logistic regressionDrug treatment programsHIV/AIDSHCV seropositivityC coinfectionHCV antibodiesHIV cohortHCV serologyAlbumin levelsLow albuminPrimary outcomePrescription refillsPoor adherenceMale genderHIV therapyEligible individuals